Topic Hub

Zoledronic Acid — Regulatory History

4 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.

4articles

36keywords mapped

2026-05-26latest review

Explore

Zoledronic Acid — Regulatory History library

Showing 4 of 4 clinical reviews.

Safety2026-05-26

Reclast (Zoledronic Acid) FAERS Safety Signals: Post-Market Surveillance Data and FDA Label Updates

A clinical review of zoledronic acid (Reclast) safety signals reported to the FDA Adverse Event Reporting System (FAERS), including osteonecrosis of the jaw, atypical femoral fractures, renal toxicity, and atrial fibrillation.

Read clinical review

Clinical Reviews2026-05-25

Reclast (Zoledronic Acid) FDA Approval History

Complete FDA approval timeline for zoledronic acid (Reclast/Zometa), including original indications, label expansions, safety communications, and post-market surveillance findings.

Read clinical review

Safety2026-05-25

Reclast (Zoledronic Acid) Global Regulatory Status: FDA Approval, EMA Authorization, and Post-Market Safety

Complete regulatory overview of zoledronic acid (Reclast/Aclasta) covering FDA approval history, EMA authorization, labeled indications, boxed warnings, and global post-market surveillance data.

Read clinical review

Questions2026-05-25

Reclast (Zoledronic Acid): Pipeline, Next-Gen Bisphosphonates, and What Comes After

A clinical overview of zoledronic acid's regulatory history, current label, post-market safety data, and the next-generation bone agents in development that may eventually succeed it.

Read clinical review